Interferons and cognition.
Cognitive impairment in multiple sclerosis is frequent, but the effect of immunomodulating drugs and mainly interferon beta (IFNbeta) on the neuropsychological aspects of the disease has not been fully studied. The data that we have are not conclusive. This paper reviews the effect of IFNbeta on cognition in the different clinical forms of the disease and the future directions of clinical trials.